ReviewBiomolecules2021

Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.

Nai-Jung Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.